5-(5-chloro-2-hydroxybenzylidene)-3-(3-nitrobenzyl)thiazolidine-2,4-dione

ID: ALA2011396

PubChem CID: 2284978

Max Phase: Preclinical

Molecular Formula: C17H11ClN2O5S

Molecular Weight: 390.80

Molecule Type: Small molecule

Associated Items:

This compound is not in our inventory system

Names and Identifiers

Canonical SMILES:  O=C1S/C(=C\c2cc(Cl)ccc2O)C(=O)N1Cc1cccc([N+](=O)[O-])c1

Standard InChI:  InChI=1S/C17H11ClN2O5S/c18-12-4-5-14(21)11(7-12)8-15-16(22)19(17(23)26-15)9-10-2-1-3-13(6-10)20(24)25/h1-8,21H,9H2/b15-8-

Standard InChI Key:  BBRNHDJYYOJNPV-NVNXTCNLSA-N

Molfile:  

     RDKit          2D

 26 28  0  0  0  0  0  0  0  0999 V2000
    8.2736  -20.2500    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.2724  -21.0773    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.9872  -21.4902    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.7037  -21.0769    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.7008  -20.2463    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.9854  -19.8372    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.4137  -19.8311    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   11.1294  -20.2410    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   11.1475  -21.0697    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
   11.9377  -21.3068    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   12.4074  -20.6284    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   11.9073  -19.9723    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   12.1460  -19.1826    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   13.2321  -20.6096    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   13.6608  -21.3145    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   13.2605  -22.0349    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   13.6885  -22.7393    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   14.5142  -22.7209    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   14.9100  -21.9922    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   14.4798  -21.2908    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   15.7392  -21.9711    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   16.1328  -21.2461    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   16.1703  -22.6745    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    8.9830  -19.0122    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    8.9870  -22.3152    0.0000 Cl  0  0  0  0  0  0  0  0  0  0  0  0
   12.2104  -22.0854    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
  6  1  1  0
 12 13  2  0
  1  2  2  0
 10 26  2  0
  5  7  1  0
 11 14  1  0
  3  4  2  0
 14 15  1  0
  7  8  2  0
 15 16  2  0
  8  9  1  0
 16 17  1  0
 17 18  2  0
  4  5  1  0
 18 19  1  0
  2  3  1  0
 19 20  2  0
 20 15  1  0
  5  6  2  0
  9 10  1  0
 10 11  1  0
 21 22  2  0
 21 23  1  0
 19 21  1  0
 11 12  1  0
  6 24  1  0
 12  8  1  0
  3 25  1  0
M  CHG  2  21   1  23  -1
M  END

Associated Targets(Human)

AMY1A Salivary alpha-amylase (100 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 390.80Molecular Weight (Monoisotopic): 390.0077AlogP: 4.19#Rotatable Bonds: 4
Polar Surface Area: 100.75Molecular Species: NEUTRALHBA: 6HBD: 1
#RO5 Violations: HBA (Lipinski): 7HBD (Lipinski): 1#RO5 Violations (Lipinski):
CX Acidic pKa: 8.57CX Basic pKa: CX LogP: 4.04CX LogD: 4.01
Aromatic Rings: 2Heavy Atoms: 26QED Weighted: 0.48Np Likeness Score: -1.97

References

1. Brvar M, Perdih A, Hodnik V, Renko M, Anderluh G, Jerala R, Solmajer T..  (2012)  In silico discovery and biophysical evaluation of novel 5-(2-hydroxybenzylidene) rhodanine inhibitors of DNA gyrase B.,  20  (8): [PMID:22444877] [10.1016/j.bmc.2012.02.052]
2. Al-Asri J, Fazekas E, Lehoczki G, Perdih A, Görick C, Melzig MF, Gyémánt G, Wolber G, Mortier J..  (2015)  From carbohydrates to drug-like fragments: Rational development of novel α-amylase inhibitors.,  23  (20): [PMID:26395057] [10.1016/j.bmc.2015.09.007]

Source